AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01378390 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Administration will be preceded by localization and closure of the internal opening following Major Ambulatory Surgery standards. Subjects will be receiving one treatment cycle with placebo consisting of intralesional instillation of 5 ml saline solution. Patients without healing (complete fistula closure) following week 12 assessment will continue to receive standard of care until the primary assessment of fistula closure at week 24. Patients with incomplete fistula closure at week 24 will be offered the possibility of participating in a separate open-label, single arm study using the ASCs derived from the liposuction procedure.
Study NCT04795804 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Human Milk Oligossaccharide
Description: The day before the CIDs, the participants receive the supplements 3x a day in randomized order
Study NCT04795804 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: The day before the CIDs, the participants receive the supplements 3x a day in randomized order
Study NCT04795804 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Human Milk Oligossaccharide and resistant starch
Description: The day before the CIDs, the participants receive the supplements 3x a day in randomized order
Study NCT00296348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: immunosuppression
Study NCT00296348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: immunosuppression
Study NCT00296348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Description: oral
Study NCT00296348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: oral
Study NCT00296348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daclizumab
Description: oral
Study NCT00296348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: steroids
Description: oral
Study NCT03704051 — intervention group
Intervention type: BEHAVIORAL
Intervention: Mode of Feeding (breastfeeding versus bottle-feeding)
Description: Infants will be breastfed during one lab visit and bottle-fed (with expressed breast-milk) during the other.
Study NCT02175667 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Global Postural Reeducation
Description: Experimental group is treated in a 45 minutes GPR session, with three postures: the first was for the anterior muscular chain with the patient lying supine on a couch with arms at 45 degrees, hips open, and feet in opposition on top of the table. This posture is maintained 25-30 minutes. The second GPR posture, to stretch the posterior muscle chain, the participant is positioned with legs elevated, for 12-15 minutes. Third position is with the participant standing and 2-5 minutes to integrate the postural corrections. During all the time, the physiotherapist use manual therapy for stretch the muscles under the official rules of GPR techniques. Group control do not receive any technique.
Study NCT04755400 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: isotonic saline 9%
Description: 1 Liter of Isotonic saline administered I.V.
Study NCT04755400 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: isotonic saline 9%
Description: 1 Liter of Isotonic saline administered I.V.
Study NCT04755400 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Potassium nitrate
Description: 24 mmol of Potassium nitrate is the active comparator substance, that is ingested every morning for 4 days before and on the examination day.
Study NCT04755400 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Potassium chloride
Description: 24 mmol of Potassium nitrate is the placebo substance, that is ingested every morning for 4 days before and on the examination day.
Study NCT04202757 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 12.5 ml/kg intravenous 0.9% sodium chloride with 0.1% riboflavin , per each of two infusions (25 ml/kg total), in combination with ongoing normal standard treatment.
Study NCT03302598 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: serum C-reactive protein
Study NCT01368354 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CLTS
Description: CLTS (Community Led Total Sanitation) involves facilitating a process to inspire and empower rural communities to stop open defecation and to build and use latrines, without offering external hardware subsidies. Communities are encouraged to appraise and analyse their own sanitation profile, including the extent of open defecation and the spread of faecal-oral contamination. This approach ignites a sense of disgust and share among the community. The community then collectively realises the impact of its unsanitary practices and this realisation mobilises and initiates collective action to improve the existing sanitation profile.
Study NCT00748696 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortimel Extra®
Description: 260kcal and 20g protein per day
Study NCT00748696 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistance training
Description: 3 sessions of resistance training per week
Study NCT00748696 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combined treatment
Description: 260kcal and 20g protein per day 3 sessions of resistance training per week
Study NCT00276536 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alpha-1b
Description: interferon
Study NCT00276536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFN
Description: IFN daily
Study NCT03528486 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Training I
Description: Participants will be attending group classes, guided by a trainer, with up to 10 other older adults.
Study NCT03528486 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music Training I
Description: Participants will be attending group classes, guided by a trainer, with up to 10 other older adults.
Study NCT01954212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced complex oral health care
Description: Our proposed complex oral health care (OHC) intervention (SOCLE intervention) comprises 3 levels of intervention:~1. Patient Level: An individualised OHC assessment on admission and individualised OHC plans for patients, which may involve staff-led OHC support, access to OHC equipment, products and specialist support services and OHC health promotion components.~2. Staff Level: Specialist web-based OHC educational training, including information on the oral cavity and structures; oral health problems (e.g. decay, gum disease, dry mouth); instruction on OHC techniques, equipment and products; use of the SOCLE assessment and protocol tools.~3. Service Level: Processes to facilitate access to specialist dental support services (e.g. dentist, hygienist, denture repair laboratory). Essential OHC equipment (toothbrushes, denture marking kits) and products (e.g. toothpaste, oral balance gel) on the ward will be available.
Study NCT04404725 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: comfilcon A
Description: Subjects will be randomized to wear comfilcon A for one month.
Study NCT04404725 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A
Description: Subjects will be randomized to wear comfilcon A for one month.
Study NCT04404725 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Samfilcon A
Description: Subjects will be randomized to wear samfilcon A for one month.
Study NCT04404725 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Samfilcon A
Description: Subjects will be randomized to wear samfilcon A for one month.
Study NCT00686764 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Using ultrasound, we will measure the cross-sectional area of the neuroma at its widest point and compare to the cross-sectional area of the same nerve at the lesser trochanter.~We will be using four different metrics for quantifying the pain experience of each subject: Questionnaire for Persons with Transfemoral Amputation (Q-FTA), Trinity Amputation and Prosthesis Experience Scales (TAPES), Visual Analog Scale (VAS), and the Short-Form 36 (SF-36).
Study NCT01316237 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GS-6620
Description: GS-6620 tablet, 50 mg QD
Study NCT01316237 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GS-6620
Description: GS-6620 tablet, 100 mg QD
Study NCT01316237 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GS-6620
Description: GS-6620 tablet, 300 mg QD
Study NCT01316237 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GS-6620
Description: GS-6620 tablet, 100 mg QD, Fasted
Study NCT01316237 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GS-6620
Description: GS-6620 tablet, 300 mg QD, Fasted
Study NCT01316237 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GS-6620
Description: GS-6620 tablet, 900 mg QD, Fasted
Study NCT01316237 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GS-6620 tablet, 450 mg BID
Description: GS-6620 tablet, 450 mg BID
Study NCT01316237 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GS-6620 tablet
Description: GS-6620 tablet, 900mg , BID
Study NCT01316237 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GS-6620 tablet
Description: GS-6620 tablet, 900 mg
Study NCT00789776 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: Undergo donor bone marrow transplantation
Study NCT00789776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT00789776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT00789776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00789776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO
Study NCT00789776 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Natural Killer Cell Therapy
Description: Given IV
Study NCT03548090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Over-ground multi-directional gait training
Description: In the over-ground multi-directional gait protocol, the participant will walk 750 steps forward, 50 steps backward, and 200 side steps over level surfaces. The over ground gait training will focus on equalizing step length while performing multi-directional gait training.
Study NCT01605305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX6
Description: OXA 100mg/m2 ivgtt 2h d1 LV 400mg/m2 ivgtt 2h d1 5FU 400mg/m2 iv. d1 5FU 2.4g/m2 civ 46h
Study NCT01438710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prograf
Description: Oral Prograf or generic tacrolimus doses will be taken b,i,d, consistently in 2 divided doses, once in the morning and once in the evening, to maintain trough level in the range of 3 to 12 ng/mL. Target trough level for the subject will be determined per clinical practice.
Study NCT01438710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCP-Tacro
Description: LCP-Tacro will be administered orally q.d. in the morning based on a conversion factor from Prograf or generic tacrolimus to LCP-Tacro of 0.7 for non-African American subjects and 0.85 for African American subjects to maintain target trough level of 3 to 12 ng/mL.
Study NCT02735317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Ulcer Gargle (FORRAD®)
Description: Oral Ulcer Gargle (FORRAD®) is prescribed at the beginning of radiotherapy for free. Patients are asked to start application of Oral Ulcer Gargle (FORRAD®) at the onset of radiotherapy, four times a day (after meals and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation-induced oral mucositis. When grade > 3 OM happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted.
Study NCT02735317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quadruple mixture, composed of dexamethasone, gentamicin, vitamin B12, and procaine
Description: Quadruple mixture is prescribed at the beginning of radiotherapy. Patients are asked to start application of quadruple mixture at the onset of radiotherapy, four times a day (before meals and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation-induced oral mucositis. When grade > 3 OM happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted.
Study NCT04516616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin+Albumin-bound paclitaxel (1 cycle) and PD-1 monoclonal antibody+Cisplatin+Albumin-bound paclitaxel (2 cycles)
Description: PD-1 monoclonal antibody （SHR-1210)：200mg，IV infusion，Q3W Cisplatin：75-80 mg/m2, IV infusion, Q3W Albumin-bound paclitaxel: 260 mg/m2，30min，IV infusion, Q3W
Study NCT03398148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab IV
Description: risankizumab intravenous (IV) infusion
Study NCT03398148 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for risankizumab
Description: placebo for risankizumab
Study NCT03398148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab SC
Description: risankizumab subcutaneous (SC) injection
Study NCT01662427 — intervention group
Intervention type: OTHER
Intervention: Questionaire to assess Noctural Parkinson's Disease Symptoms
Description: Questionaire to assess Noctural Parkinson's Disease Symptoms and quality of life
Study NCT00559910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: PH-797804 at four dose levels
Study NCT00559910 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03442127 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CaringGuidance™ After Breast Cancer Diagnosis
Description: Web-based, psychoeducational, self-management tool
Study NCT00911924 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStent
Description: Glaukos iStent, medication
Study NCT02606773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ascorbic Acid
Description: Ascorbic acid in different ways and doses
Study NCT02606773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Ascorbic acid in different ways and doses
Study NCT01656603 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: unlicensed CBU
Description: infusion of unlicensed cord blood units
Study NCT03565861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous vehicle
Study NCT03565861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP10679
Description: NP10679
Study NCT00107380 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Study NCT00107380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00107380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study NCT00107380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Study NCT00107380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT00107380 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: tositumomab and iodine I 131 tositumomab
Study NCT00548275 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Sexual Risk Management
Description: management of sexual risk
Study NCT00548275 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Sexual Risk Management
Description: management of sexual risk
Study NCT02078310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-007
Description: ITI-007 for Part 1
Study NCT02078310 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ITI-007 for Part 1
Study NCT02078310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-007
Description: ITI-007 for Part 2
Study NCT02078310 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Part 2
Study NCT06781164 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: telemedicine
Description: Recording of the ear of each patient with an ear problem
Study NCT04388657 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echo-Doppler
Description: Utrasound Doppler of the lower limbs
Study NCT00789776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO
Study NCT00789776 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo total-body irradiation
Study NCT01232244 — intervention group
Intervention type: OTHER
Intervention: GLP-1 infusion
Description: 1 pmol/kg/min
Study NCT01232244 — intervention group
Intervention type: OTHER
Intervention: Glucagon infusion
Description: 3ng/kg/min
Study NCT01232244 — intervention group
Intervention type: OTHER
Intervention: Oxyntomodulin infusion
Description: 3 pmol/kg/min
Study NCT01232244 — intervention group
Intervention type: OTHER
Intervention: GLP-1 and glucagon infusion
Description: 1 pmol/kg/min 3 ng/kg/min
Study NCT01232244 — intervention group
Intervention type: OTHER
Intervention: Placebo
Description: NaCl 9 g/L infusion
Study NCT04345133 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Dental Implants Insertion Drilling Sequence
Description: Drilling sequence protocol to insert immediate Dental Implants at the Maxilla.
Study NCT04345133 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Implants Insertion Drilling Sequence
Description: Drilling sequence protocol to insert immediate Dental Implants at the Maxilla.
Study NCT03053245 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Critical Care Program
Description: The m-CCRP revolves around the central figure of a care coordinator who will organize and align recovery resources. The care coordinator is a registered nurse whose scope of practice includes health coaching, case managing, community organizing, and nursing care provider. The m-CCRP support team will consist of a critical care physician (Dr. Khan), a geriatrician with expertise in collaborative care (Dr. Boustani), an ICU collaborative care nurse (Dr. Lasiter), and a psychologist (Dr. Unverzagt). This team will meet weekly with the care coordinator. Drs. Khan and Boustani will be accessible to the coordinator through phone or pager at all times.
Study NCT03053245 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Patients in this group will receive regular wellness calls from the research team.
Study NCT02625298 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProRoot MTA
Description: Apical thirds of the root canals obturated with ProRoot MTA (Dentsply Tulsa Dental Specialties, Tulsa, OK USA).
Study NCT02625298 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MTA+ Cerkamed
Description: Apical thirds of the root canals obturated with MTA + (Cerkamed, Stalowa Wola, Poland).
Study NCT01662011 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mode of neurally adjusted ventilatory assist
Description: patients ventilated with the mode of neurally adjusted ventilatory assist after corrective open-heart surgery
Study NCT01662011 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mode of pressure support ventilation
Description: Patients ventilated with the mode of pressure support ventilation after corrective open-heart surgery
Study NCT03695354 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: whole body vibration plus conventional therapy
Description: Subjects enrolled in whole body vibration training group are exposed to side-to-side alternating vertical sinusoidal vibration. Galileo system(Novotec Medical GmbH, Pforzheim, Germany) is used to training. Frequency of whole body vibration is 12Hz and amplitude is 4mm. After 10 minutes of vibration training, subjects rest 3 minutes. Then, additional 10 minutes of training will be given.~conventional physical therapy is consisted of passive range of motion exercise and walking exercise.
Study NCT03695354 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: conventional physical therapy is consisted of passive range of motion exercise and walking exercise.
Study NCT00178711 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hypothermia
Description: Induction of moderate hypothermia to 33 degrees celsius, within 2.5 hours from time of injury and maintained for 48 hours
Study NCT04129528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CFZ533
Description: First dose is administered via intravenous infusion, subsequent doses are administered subcutaneously.
Study NCT04129528 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for active drug